HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 19196727.
- Also identified by DOI 10.1136/ard.2008.096495.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Monitoring of peripheral B-cell subsets in patients with systemic lupus erythematosus (SLE) revealed an activity-related expansion of CD27(++)CD20(-)CD19(dim) Ig-secreting cells. A similar subset has also been identified 6-8 days after tetanus/diphtheria vaccination in normal individuals and in patients with infectious disease. This subset was analysed further focussing on the HLA-DR surface expression in a cohort of 25 patients with SLE. This study revealed that 86% (range 59-97%) of CD27(++)CD20(-)CD19(dim) cells express high levels of HLA-DR, are also expanded in the bone marrow, and represent plasmablasts enriched with anti-dsDNA secreting cells. The remaining CD27(++)CD20(-)CD19(dim) cells were HLA-DR(low) and represent mature plasma cells. Importantly, HLA-DR(high) plasmablasts showed a closer correlation with lupus activity and anti-dsDNA levels than the previously identified CD27(++)CD20(-)CD19(dim) cells. HLA-DR(high)CD27(++)CD20(-)CD19(dim) plasmablasts represent a more precise indicator of lupus activity and suggest that there is an overproduction or lack of negative selection of these cells in SLE.
Medical subject headings
- B-Lymphocyte Subsets
- HLA-DR Antigens
- Lupus Erythematosus, Systemic
- Tumor Necrosis Factor Receptor Superfamily, Member 7